NCT02023905View on ClinicalTrials.gov

Everolimus With and Without Temozolomide in Adult Low Grade Glioma

PHASE2TerminatedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

March 19, 2014

Primary Completion Date

September 30, 2021

Study Completion Date

September 30, 2021

Conditions
Low Grade GliomaWorld Health Organization (WHO) Grade II AstrocytomasOligodendrogliomasMixed Oligoastrocytomas
Interventions
DRUG

Everolimus

everolimus at 10 mg daily continuously

DRUG

Temozolomide

Temozolomide will be dosed initially at 150 mg/m2/day for 5 days out of a 28-day cycle. TMZ will be stopped after 12 cycles

Trial Locations (1)

94143

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

University of California, San Francisco

OTHER